8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Jan 30, 2026·SEC
OmniAb, Inc.(OABI)Earnings, Financials & Key Ratios
OABI•NASDAQ
Price updated Jun 19, 2026
AboutOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Show more
- Revenue$19M-29.3%
- EBITDA-$50M+2.3%
- Net Income-$65M-4.4%
- EPS (Diluted)-0.57+6.6%
- Gross Margin-18.17%-118.2%
- EBITDA Margin-266.6%-38.2%
- Operating Margin-383.15%-35.7%
- Net Margin-347.04%-47.6%
- ROE-23.36%-13.4%
OABI Key Insights
OmniAb, Inc. (OABI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Profits declining 29.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 11.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OABI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OABI Price & Volume
OmniAb, Inc. (OABI) stock price & volume — 10-year historical chart
Loading chart...
OABI Growth Metrics
OmniAb, Inc. (OABI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-4.31%
3 Years-31.89%
TTM8.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.69%
Return on Capital
10 Years-14.31%
5 Years-17.11%
3 Years-21.7%
Last Year-24.03%
OABI Recent Earnings
OmniAb, Inc. (OABI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.06+40.0%
$0.10
Rev
$14M+157.6%
$6M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.11-37.5%
$0.08
Rev
$8M-7.0%
$9M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.14-2.9%
$0.14
Rev
$2M-60.3%
$6M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.15-7.1%
$0.14
Rev
$4M-31.0%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.06vs $0.10+40.0% | $14Mvs $6M+157.6% |
| Q2 2026 | Mar 4, 2026 | $0.11vs $0.08-37.5% | $8Mvs $9M-7.0% |
| Q4 2025 | Nov 4, 2025 | $0.14vs $0.14-2.9% | $2Mvs $6M-60.3% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.14-7.1% | $4Mvs $6M-31.0% |
Based on last 12 quarters of dataView full earnings history →
OABI Peer Comparison
OmniAb, Inc. (OABI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABCL | 1.69B | 5.53 | -11.29 | 160.56% | -181.75% | -14.22% | 0.13 | |
 TWST | 5.45B | 87.56 | -67.35 | 20.32% | -19.85% | -17.46% | 0.29 | |
 SEER | 95.67M | 1.74 | -1.36 | 15.57% | -468.74% | -26.58% | 0.09 |
Compare OABI vs Peers
OmniAb, Inc. (OABI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OABI Income Statement
OmniAb, Inc. (OABI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 18.32M | 23.27M | 34.75M | 59.08M | 34.16M | 26.39M | 18.67M | 28.91M |
Revenue Growth % | - | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% | -29.27% | 8.11% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 22.06M | 18.66M |
COGS % of Revenue | - | - | - | - | - | - | 118.17% | - |
Gross Profit | 18.32M▲ 0% | 23.27M▲ 27.0% | 34.75M▲ 49.3% | 59.08M▲ 70.0% | 34.16M▼ 42.2% | 26.39M▼ 22.8% | -3.39M▼ 112.8% | 10.25M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | -18.17% | 35.45% |
Gross Profit Growth % | - | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% | -112.85% | - |
Operating Expenses | 31.34M | 48.89M | 70.36M | 85.72M | 103.58M | 100.89M | 68.13M | 68.17M |
OpEx % of Revenue | 171.12% | 210.12% | 202.48% | 145.11% | 303.19% | 382.3% | 364.98% | - |
Selling, General & Admin | 8.65M | 10.22M | 16.95M | 24.9M | 33.31M | 30.74M | 29.21M | 26.47M |
SG&A % of Revenue | 47.23% | 43.94% | 48.77% | 42.15% | 97.51% | 116.48% | 156.51% | - |
Research & Development | 13.21M | 24.8M | 39.23M | 48.36M | 56.52M | 55.11M | 47.75M | 44.75M |
R&D % of Revenue | 72.1% | 106.57% | 112.9% | 81.87% | 165.45% | 208.82% | 255.83% | - |
Other Operating Expenses | 9.49M | 13.87M | 14.18M | 12.46M | 13.74M | 15.04M | -8.84M | 110K |
Operating Income | -13.03M▲ 0% | -25.62M▼ 96.7% | -35.61M▼ 39.0% | -26.65M▲ 25.2% | -69.42M▼ 160.5% | -74.5M▼ 7.3% | -71.52M▲ 4.0% | -57.92M▲ 0% |
Operating Margin % | -71.12% | -110.12% | -102.48% | -45.11% | -203.19% | -282.3% | -383.15% | -200.35% |
Operating Income Growth % | - | -96.69% | -38.97% | 25.16% | -160.5% | -7.32% | 4.01% | - |
EBITDA | -2.43M | -13M | -19.36M | -8.4M | -49.92M | -50.92M | -49.76M | -34.91M |
EBITDA Margin % | -13.29% | -55.85% | -55.71% | -14.22% | -146.12% | -192.94% | -266.6% | -120.76% |
EBITDA Growth % | - | -433.94% | -48.95% | 56.61% | -494.38% | -2% | 2.27% | 26.37% |
D&A (Non-Cash Add-back) | 10.59M | 12.63M | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M | 23.01M |
EBIT | -13.85M | -23.55M | -34.34M | -26.65M | -69.42M | -74.5M | -71.52M | -58.13M |
Net Interest Income | 0 | -5K | -7K | 587K | 5.05M | 3.11M | 2.66M | 2.32M |
Interest Income | 0 | 0 | 0 | 587K | 5.05M | 3.11M | 2.66M | 2.32M |
Interest Expense | 0 | 5K | 7K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 0 | 1.9M | 1.26M | 587K | 5.06M | 3.09M | 5.22M | 4.56M |
Pretax Income | -13.03M▲ 0% | -23.73M▼ 82.1% | -34.35M▼ 44.8% | -26.06M▲ 24.1% | -64.36M▼ 147.0% | -71.41M▼ 11.0% | -66.29M▲ 7.2% | -53.37M▲ 0% |
Pretax Margin % | -71.12% | -101.98% | -98.85% | -44.11% | -188.39% | -270.59% | -355.16% | -184.58% |
Income Tax | 562K | -6.17M | -7.31M | -3.73M | -13.74M | -9.38M | -1.51M | 913K |
Effective Tax Rate % | -4.31% | 26.01% | 21.28% | 14.3% | 21.35% | 13.13% | 2.29% | -1.71% |
Net Income | -13.59M▲ 0% | -17.56M▼ 29.2% | -27.04M▼ 54.0% | -22.33M▲ 17.4% | -50.62M▼ 126.6% | -62.03M▼ 22.5% | -64.78M▼ 4.4% | -54.28M▲ 0% |
Net Margin % | -74.18% | -75.46% | -77.82% | -37.8% | -148.16% | -235.05% | -347.04% | -187.74% |
Net Income Growth % | - | -29.2% | -54.02% | 17.41% | -126.65% | -22.55% | -4.43% | 11.41% |
Net Income (Continuing) | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M | -64.78M | -54.28M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.12▲ 0% | -0.15▼ 25.0% | -0.24▼ 60.0% | -0.26▼ 8.3% | -0.51▼ 96.2% | -0.61▼ 19.6% | -0.57▲ 6.6% | -0.42▲ 0% |
EPS Growth % | - | -25% | -60% | -8.33% | -96.15% | -19.61% | 6.56% | 20.69% |
EPS (Basic) | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 | -0.57 | - |
Diluted Shares Outstanding | 114.82M | 114.82M | 114.82M | 85.32M | 99.68M | 102.36M | 113.64M | 128.33M |
Basic Shares Outstanding | 114.82M | 114.82M | 114.82M | 85.32M | 99.68M | 102.36M | 113.64M | 128.33M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
OABI Balance Sheet
OmniAb, Inc. (OABI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.79M | 16.65M | 22.54M | 124.95M | 94.9M | 68.14M | 65.34M | 65.13M |
Cash & Short-Term Investments | 0 | 0 | 0 | 88.27M | 86.98M | 59.43M | 54.02M | 49.07M |
Cash Only | 0 | 0 | 0 | 33.39M | 16.36M | 27.6M | 25.52M | 29.05M |
Short-Term Investments | 0 | 0 | 0 | 54.88M | 70.63M | 31.84M | 28.5M | 20.03M |
Accounts Receivable | 7.77M | 15.88M | 21.14M | 30.29M | 3.84M | 5.27M | 7.39M | 12.64M |
Days Sales Outstanding | 154.9 | 249.03 | 222.02 | 187.14 | 41.07 | 72.91 | 144.51 | 81.52 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 21K | 774K | 1.41M | 6.39M | 4.07M | 3.43M | 3.93M | 3.41M |
Total Non-Current Assets | 254.53M | 278.73M | 281.92M | 296.26M | 280.32M | 257.42M | 235.57M | 228.53M |
Property, Plant & Equipment | 4.32M | 5.98M | 20.13M | 41.46M | 38.13M | 33.28M | 24.97M | 24.07M |
Fixed Asset Turnover | 4.24x | 3.89x | 1.73x | 1.42x | 0.90x | 0.79x | 0.75x | 1.06x |
Goodwill | 77.11M | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M |
Intangible Assets | 172.98M | 186.64M | 176.32M | 167.24M | 155.47M | 138.06M | 125.15M | 119.12M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 560K |
Other Non-Current Assets | 115K | 2.13M | 1.5M | 3.58M | 2.75M | 2.1M | 1.47M | 1.35M |
Total Assets | 262.32M▲ 0% | 295.38M▲ 12.6% | 304.46M▲ 3.1% | 421.21M▲ 38.3% | 375.23M▼ 10.9% | 325.56M▼ 13.2% | 300.91M▼ 7.6% | 293.65M▲ 0% |
Asset Turnover | 0.07x | 0.08x | 0.11x | 0.14x | 0.09x | 0.08x | 0.06x | 0.10x |
Asset Growth % | - | 12.6% | 3.08% | 38.34% | -10.92% | -13.24% | -7.57% | -30.59% |
Total Current Liabilities | 6.14M | 14.28M | 20.58M | 26.02M | 23.12M | 15.09M | 16.25M | 13.57M |
Accounts Payable | 806K | 469K | 2.92M | 2.97M | 4.41M | 2.3M | 1.88M | 1.65M |
Days Payables Outstanding | - | - | - | - | - | - | 31.09 | 36.26 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.88M | 3.94M |
Deferred Revenue (Current) | 0 | 7.16M | 10.79M | 8.21M | 6.85M | 2.34M | 3.16M | 8.72M |
Other Current Liabilities | 4.55M | 3.79M | 4.92M | 8.18M | 7.8M | 6.67M | 7.33M | 5.03M |
Current Ratio | 1.27x | 1.17x | 1.10x | 4.80x | 4.11x | 4.52x | 4.02x | 4.80x |
Quick Ratio | 1.27x | 1.17x | 1.10x | 4.80x | 4.11x | 4.52x | 4.02x | 4.80x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 45.26 |
Total Non-Current Liabilities | 38M | 45.57M | 49.58M | 53.82M | 37.52M | 22.85M | 17.63M | 17.44M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.73M |
Capital Lease Obligations | 2.27M | 2.01M | 13.27M | 24.02M | 22.07M | 19.38M | 16.45M | 51.6M |
Deferred Tax Liabilities | 0 | 28.93M | 21.96M | 21.34M | 11.35M | 2.31M | 785K | 5.5M |
Other Non-Current Liabilities | 35.72M | 6.4M | 5.12M | 4.13M | 3.23M | 1.04M | 393K | 481K |
Total Liabilities | 44.13M | 59.84M | 70.16M | 79.84M | 60.64M | 37.94M | 33.89M | 31M |
Total Debt | 2.58M | 2.59M | 13.85M | 25.8M | 25.56M | 23.16M | 20.33M | 19.67M |
Net Debt | 2.58M | 2.59M | 13.85M | -7.59M | 9.2M | -4.43M | -5.19M | -9.38M |
Debt / Equity | 0.01x | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x | 0.08x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.56x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.27x |
Interest Coverage | - | -4710.60x | -4906.14x | - | - | - | - | - |
Total Equity | 218.19M▲ 0% | 235.54M▲ 8.0% | 234.31M▼ 0.5% | 341.37M▲ 45.7% | 314.58M▼ 7.8% | 287.62M▼ 8.6% | 267.03M▼ 7.2% | 262.65M▲ 0% |
Equity Growth % | - | 7.95% | -0.52% | 45.69% | -7.85% | -8.57% | -7.16% | -26.95% |
Book Value per Share | 1.90 | 2.05 | 2.04 | 4.00 | 3.16 | 2.81 | 2.35 | 2.05 |
Total Shareholders' Equity | 218.19M | 235.54M | 234.31M | 341.37M | 314.58M | 287.62M | 267.03M | 262.65M |
Common Stock | 218.19M | 0 | 0 | 12K | 12K | 12K | 14K | 14K |
Retained Earnings | 0 | 0 | 0 | 11.25M | -39.37M | -101.4M | -166.18M | -173.89M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 9K | 50K | 27K | 12K | -2K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OABI Cash Flow Statement
OmniAb, Inc. (OABI) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.2M | 3.62M | -5.67M | -3.59M | 2.35M | -39.66M | -36.45M | -25.5M |
Operating CF Margin % | -28.36% | 15.55% | -16.32% | -6.07% | 6.87% | -150.29% | -195.3% | - |
Operating CF Growth % | - | 169.66% | -256.73% | 36.76% | 165.43% | -1789.99% | 8.09% | 31.84% |
Net Income | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M | -64.78M | -54.28M |
Depreciation & Amortization | 10.92M | 13.14M | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M | 23.64M |
Stock-Based Compensation | 6.66M | 9.16M | 15.06M | 18.32M | 24.82M | 21.5M | 15.82M | 11.06M |
Deferred Taxes | 557K | -6.18M | -7.33M | -6.42M | -12.54M | -9.04M | 0 | -1.27M |
Other Non-Cash Items | -818K | 331K | 9K | -572K | -3.68M | -3.5M | -4.3M | 2.65M |
Working Capital Changes | -8.92M | 4.73M | -2.63M | -10.83M | 24.87M | -10.17M | -4.95M | -7.29M |
Change in Receivables | -4.29M | 339K | 6.02M | -12.74M | 26.9M | -625K | 189K | -4.26M |
Change in Inventory | 0 | 0 | -1.51M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 1.51M | 15.07M | 920K | -2.41M | -231K | 215K |
Cash from Investing | -12.1M | -26.98M | -4.03M | -73.31M | -18.38M | 37.88M | 6.47M | 15.78M |
Capital Expenditures | -255K | -1.75M | -4.07M | -17.17M | -1.64M | -1.88M | -565K | -523K |
CapEx % of Revenue | 1.39% | 7.53% | 11.71% | 29.06% | 4.81% | 7.1% | 3.03% | 1.81% |
Acquisitions | -11.84M | -27.13M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 1.9M | -1.22M | -1.44M | -4.44M | -400K | 3M | 3M |
Cash from Financing | 17.29M | 23.36M | 9.7M | 110.74M | -892K | 13.02M | 27.91M | 27.87M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 96.24M | 0 | 11.37M | 28.36M | 28.32M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 17.29M | 23.36M | 9.7M | 14.5M | -892K | 1.65M | -450K | -450K |
Net Change in Cash | 0▲ 0% | 0▲ 0% | 0▲ 0% | 33.84M▲ 0% | -16.92M▼ 150.0% | 11.24M▲ 166.4% | -2.07M▼ 118.5% | 18.15M▲ 0% |
Free Cash Flow | -5.45M▲ 0% | 1.87M▲ 134.2% | -9.74M▼ 622.1% | -20.75M▼ 113.0% | 703K▲ 103.4% | -41.54M▼ 6008.8% | -37.02M▲ 10.9% | -26.02M▲ 0% |
FCF Margin % | -29.75% | 8.02% | -28.04% | -35.13% | 2.06% | -157.4% | -198.33% | -90% |
FCF Growth % | - | 134.24% | -622.08% | -113.05% | 103.39% | -6008.82% | 10.88% | 34.4% |
FCF per Share | -0.05 | 0.02 | -0.08 | -0.24 | 0.01 | -0.41 | -0.33 | -0.20 |
FCF Conversion (FCF/Net Income) | 0.38x | -0.21x | 0.21x | 0.16x | -0.05x | 0.64x | 0.56x | 0.48x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 2.61M | 16K | 0 | 0 |
OABI Key Ratios
OmniAb, Inc. (OABI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -7.74% | -11.51% | -7.76% | -15.43% | -20.6% | -23.36% | -20.31% |
Return on Invested Capital (ROIC) | -8.38% | -10.98% | -6.87% | -15.84% | -18.41% | -19.68% | -16.54% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | -18.17% | 35.45% |
Net Margin | -75.46% | -77.82% | -37.8% | -148.16% | -235.05% | -347.04% | -187.74% |
Debt / Equity | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x | 0.08x | 0.07x |
Interest Coverage | -4710.60x | -4906.14x | - | - | - | - | - |
FCF Conversion | -0.21x | 0.21x | 0.16x | -0.05x | 0.64x | 0.56x | 0.48x |
Revenue Growth | 27.02% | 49.34% | 70.02% | -42.17% | -22.75% | -29.27% | 8.11% |
Related:OABI Dividend History·OABI Revenue History·OABI Price History·OABI P/E History·OABI Financial Ratios·OABI Institutional Holders
OABI SEC Filings & Documents
OmniAb, Inc. (OABI) SEC filings — annual & quarterly reports (10-K, 10-Q)
OABI Frequently Asked Questions
OmniAb, Inc. (OABI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OmniAb, Inc. (OABI) reported $28.9M in revenue for fiscal year 2025. This represents a 58% increase from $18.3M in 2019.
OmniAb, Inc. (OABI) saw revenue decline by 29.3% over the past year.
OmniAb, Inc. (OABI) reported a net loss of $54.3M for fiscal year 2025.
Dividend & Returns
OmniAb, Inc. (OABI) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.
OmniAb, Inc. (OABI) had negative free cash flow of $26.0M in fiscal year 2025, likely due to heavy capital investments.